Beijing Business Daily News (Reporter Dong Liang Ding Ning) On the evening of March 27, Jingxin Pharmaceutical (002020) disclosed an announcement that recently, the company noticed on the Internet that “the company has the raw materials of trifluorobenzoyl chloride new crown medicine. “Jingxin Pharmaceutical” and “Jingxin Pharmaceutical Co., Ltd. both owns the only target of the key intermediates of Shionogi/Pfizer’s new crown drug” and other rumors. Jingxin Pharmaceutical has clarified this. The company’s raw materials are mainly quinolones, statins, and psychoneurotic drugs. At present, the company and its subsidiaries have not cooperated with Shionogi and Pfizer on new crown drugs.
It is worth noting that the stock price of Jingxin Pharmaceutical has risen sharply recently. On March 24 and March 25, the closing price of the company’s stock trading price increased by more than 20%, which is an abnormal fluctuation of stock trading.
Jingxin Pharmaceutical reminded the risk that the 2,4,5-trifluorobenzoyl chloride planned by the company’s Shandong base was a key intermediate for the preparation of 2,4,5-trifluorobenzyl bromide, and it was still in production. It takes a certain period of time, and it is expected that there will be no material impact on the company’s performance in 2022, and there will be great uncertainty on the impact on the company’s subsequent annual performance.